

## BARICITINIB tablets (Olumiant® ▼) for atopic dermatitis

**The Pan Mersey Area Prescribing Committee recommends the prescribing of BARICITINIB tablets (Olumiant® ▼), by specialists only, for atopic dermatitis in accordance with NICE TA681.**

### RED

[NICE technology appraisal \(TA\) 681](#) recommends baricitinib as an option for treating moderate to severe atopic dermatitis in adults, only if:

- > the disease has not responded to at least 1 systemic immunosuppressant, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are not suitable, **and**
- > the company provides it according to the commercial arrangement.

Assess response from 8 weeks and stop baricitinib if there has not been an adequate response at 16 weeks, defined as a reduction of at least:

- > 50% in the Eczema Area and Severity Index score (EASI 50) from when treatment started **and**
- > 4 points in the Dermatology Life Quality Index (DLQI) from when treatment started.<sup>[1]</sup>

Prescribing and monitoring must be retained by a specialist in the management of atopic dermatitis.

The NICE resource impact template estimates that by 2024/25, 3 patients per 100,000 will be treated with baricitinib instead of dupilumab at a saving of £3,079.00 per 100,000 population (once the PAS price and other associated costs are taken into account).

### References

1. National Institute for Health and Care Excellence. Technology Appraisal 681; [Baricitinib for treating moderate to severe atopic dermatitis](#), 03 March 2021. Accessed online 03 March 2021.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.